INSMInsmed Incorporated

$31B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$142M+52.4% YoY

Gross Profit

$113M79.4% margin

Operating Income

-$366M-257.1% margin

Net Income

-$370M-260.0% margin

EPS (Diluted)

$-1.75

QoQ Revenue Growth

+32.5%

Cash Flow

Operating Cash Flow

-$220M

Free Cash Flow

-$222M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$1.4B

Stockholders' Equity

$946M

Cash & Equivalents

$335M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$142M	$93M	+52.4%
Gross Profit	$113M	$72M	+56.4%
Operating Income	-$366M	-$213M	-71.5%
Net Income	-$370M	-$221M	-67.8%

Geographic Segments

UNITED STATES

$102M72%

Non-US

$40M28%

INSM Q3 2025 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena